These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15219643)

  • 41. Growth hormone provocation tests and their prediction in the growth of children treated for acute lymphoblastic leukemia.
    Papadia C; Naves LA; Motta LD; Barboza Filho RF; Suzuki MT; Casulari LA
    Minerva Endocrinol; 2006 Sep; 31(3):211-8. PubMed ID: 17213788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M; Namiki C; Thuy DH; Yoshida H; Kawasaki K; Hashikawa K; Fukuyama H; Kita T
    J Neurol Sci; 2004 Oct; 225(1-2):135-41. PubMed ID: 15465097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients.
    Hernanz A; De la Fuente M; Navarro M; Frank A
    Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease.
    Monji A; Takita M; Samejima T; Takaishi T; Hashimoto K; Matsunaga H; Oda M; Sumida Y; Mizoguchi Y; Kato T; Horikawa H; Kanba S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):308-11. PubMed ID: 19138715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is functional decline necessary for a diagnosis of Alzheimer's disease?
    Park KW; Pavlik VN; Rountree SD; Darby EJ; Doody RS
    Dement Geriatr Cogn Disord; 2007; 24(5):375-9. PubMed ID: 17914262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia.
    Srikanth S; Nagaraja AV; Ratnavalli E
    J Neurol Sci; 2005 Sep; 236(1-2):43-8. PubMed ID: 15964021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Confabulations in remembering past and planning future are associated with psychiatric symptoms in Alzheimer's disease.
    Lee E; Akanuma K; Meguro M; Ishii H; Yamaguchi S; Meguro K
    Arch Clin Neuropsychol; 2007 Nov; 22(8):949-56. PubMed ID: 17913452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
    Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
    J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study.
    Tatsumi H; Nakaaki S; Torii K; Shinagawa Y; Watanabe N; Murata Y; Sato J; Mimura M; Furukawa TA
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):374-84. PubMed ID: 19566770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
    Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
    Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease.
    Obermayr RP; Mayerhofer L; Knechtelsdorfer M; Mersich N; Huber ER; Geyer G; Tragl KH
    Exp Gerontol; 2005 Mar; 40(3):157-63. PubMed ID: 15763392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Components of behavioral pathology in dementia.
    Schreinzer D; Ballaban T; Brannath W; Lang T; Hilger E; Fasching P; Fischer P
    Int J Geriatr Psychiatry; 2005 Feb; 20(2):137-45. PubMed ID: 15660411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia.
    Pellecchia MT; Pivonello R; Salvatore E; Faggiano A; Barone P; De Michele G; Lombardi G; Colao A; Filla A
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):428-33. PubMed ID: 15807873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delusional misidentification and aggression in Alzheimer's disease.
    Silva JA; Leong GB; Weinstock R; Ruiz-Sweeney M
    J Forensic Sci; 2001 May; 46(3):581-5. PubMed ID: 11372992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression.
    Wang LY; Shofer JB; Rohde K; Hart KL; Hoff DJ; McFall YH; Raskind MA; Peskind ER
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):744-51. PubMed ID: 19700947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blunted growth hormone response to clonidine in post-traumatic stress disorder.
    Morris P; Hopwood M; Maguire K; Norman T; Schweitzer I
    Psychoneuroendocrinology; 2004 Feb; 29(2):269-78. PubMed ID: 14604605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The stability of plasma growth hormone and MHPG responses to repeated clonidine challenge in normal males.
    Trestman RL; Coccaro EF; Lawrence T; Knott P; Gabriel SM; Siever LJ
    Psychoneuroendocrinology; 1994; 19(1):13-20. PubMed ID: 9210208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detecting the effect of Alzheimer's disease on everyday motion behavior.
    Kirste T; Hoffmeyer A; Koldrack P; Bauer A; Schubert S; Schröder S; Teipel S
    J Alzheimers Dis; 2014; 38(1):121-32. PubMed ID: 24077435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clonidine-induced growth hormone secretion in elderly patients with senile dementia of the Alzheimer type and major depressive disorder.
    Gilles C; Ryckaert P; De Mol J; de Maertelaere V; Mendlewicz J
    Psychiatry Res; 1989 Mar; 27(3):277-86. PubMed ID: 2710869
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth hormone stimulation testing with oral clonidine: 90 minutes is the preferred duration for the assessment of growth hormone reserve.
    Morris AH; Harrington MH; Churchill DL; Olshan JS
    J Pediatr Endocrinol Metab; 2001; 14(9):1657-60. PubMed ID: 11795657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.